Skip to main content
Shahky Early Access Program Now Available—Sign-up to Learn More
Shahky Early Access Program Now Available—Sign-up to Learn More
 

Liquid Biopsy Mutation Detection Panel

Our liquid biopsy mutation detection panel covers 26 of the most important genes and more than 1000 associated mutations in the most significant pathways of cancer, including EGFR/MAPK and PI3K. Using plasma from a simple blood tube, the panel utilizes Exolution PlusTM, our unique extraction technology platform to simultaneously isolate exosomal RNA (exoRNA) and cell-free DNA (cfDNA), two biologically distinct sources of circulating nucleic acids. Combining exoRNA and cfDNA in a single step enables our panel to achieve ultra-sensitive detection of rare cancer mutations. 

Key Benefits

  • Plasma-based liquid biopsy test using a simple blood draw; eliminating the need for tissue samples
  • Analyzes stable, high-quality exoRNA and cfDNA for highly sensitive mutation detection
  • Simultaneously detects fusion transcripts and point mutations 
  • Covers 26 of the most important genes and more than 1000 associated mutations
  • Detects most actionable mutations with clinical relevance; EGFR/MAPK and PI3K pathways
  • Quick Turn Around Time and patient stratification for clinical trials
  • Allows longitudinal and serial monitoring throughout the clinical trial process
  • Can utilize fresh or frozen/archived plasma samples

Data

In a study presented at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, our liquid biopsy panel for solid tumors demonstrated the ability to provide robust, highly sensitive detection of actionable mutations, including KRAS, BRAF and EGFR, across multiple cancers such as melanoma, colorectal cancer, and lung cancer. Learn More

Utilizing the combined capture and subsequent isolation of exoRNA and cfDNA from plasma, the panel’s technology substantially increased the number of gene copies available for low abundant somatic mutation detection versus cfDNA alone, helping ensure that the mutation would not be missed or overlooked. In the BRAF-specific data, the technology platform enabled longitudinal monitoring of BRAF mutant melanoma and demonstrated the ability to detect early disease progression prior to clinical evidence or radiographic changes. Learn More